Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Overview | Financials
Company Name Nurix Therapeutics, Inc.
Symbol NRIX
Currency USD
Price 15.46
Market Cap 759,871,368
Dividend Yield 0%
52-week-range 4.22 - 18.12
Industry Biotechnology
Sector Healthcare
CEO Dr. Arthur T. Sands M.D., Ph.D.
Website https://www.nurixtx.com

An error occurred while fetching data.

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable

Related Stocks

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

3.88 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

30.47 USD

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

0.679 USD

OptimizeRx Corporation logo

OptimizeRx Corporation

OPRX

10.32 USD

Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

JANX

51.86 USD

Immatics N.V. logo

Immatics N.V.

IMTX

10.4 USD

Seer, Inc. logo

Seer, Inc.

SEER

1.79 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

1.155 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

2.46 USD

Financials

Numbers are in millions USD

Numbers are in millions USD